drugset / Trial / NCT07534644
A Phase I/Ⅱ Clinical Trial for Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in the Treatment of Ankylosing Spondylitis
Phase 1/2
Not yet recruiting
18 enrolled
Shenzhen Huishan Biotechnology Co., Ltd.
Southern Medical University, China · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of human umbilical cord mesenchymal stem cell injection (HS\_SW01 cells injection) in patients with Ankylosing Spondylitis. Participants will be required to sign the informed consent form and will only be assigned to the study and enrolled after undergoing a series of tests and meeting the inclusion and exclusion criteria of the protocol.
Timeline
- Start
- 2026-04-10
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HS_SW01 cells injection | Cell therapy | 1 cells/kg | Intravenous |
| Subject | HS_SW01 cells injection | Cell therapy | 2 cells/kg | Intravenous |
| Subject | HS_SW01 cells injection | Cell therapy | 3 cells/kg | Intravenous |